Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Pexa-Vec followed by sorafenib versus sorafenib alone in advanced hepatocellular carcinoma
MOH_2017-03-08_000218Phase 3Recruiting
- Sponsor
- SillaJen
- Start
- Feb 2016
- Modality
- Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Pexa-Vec followed by sorafenib with Sorafenib alone (2 arms). Started Feb 2016; status: recruiting.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virussorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2017-03-08_000218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-08_000218.